I’m Andreas Hadjivasiliou. I’m a senior specialist in the content strategy team here at Evaluate.

Evaluate is a leading provider of consensus forecasts to the industry. We source our content from leading equity analysts, and then we shape those into a consensus forecast to reflect the market view of the pharmaceutical industry.

When it comes to orphan drugs, in the report and in our content, we apply a vigorous methodology to identify which drugs qualify as orphan drugs. We look at lifetime sales by indication and establish a 50% threshold for inclusion as an orphan drug. We also look at some of the diseases which these drugs are designated for and make critical decisions on whether they should be included as a true orphan drug or not.

All of this work, curation and methodology helps us build a robust picture of the orphan drug pipeline, the orphan drug market. This allows our clients to horizon-scan, identify licensing opportunities, and supports high level and high value decision making by senior executives.